Top

Published in:

01-04-2017 | Review Article

Flibanserin and its discontents

Authors: Awais Aftab, Cheryl Chen, Jacob McBride

Published in: Archives of Women's Mental Health | Issue 2/2017

Abstract

In August 2015, flibanserin (brand name Addyi) was approved by the Food and Drug Administration (FDA) for treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. This article summarizes and promotes discussion regarding the numerous controversies that have enclosed flibanserin since the very beginning. This includes questions related to flibanserin’s safety and efficacy and the validity of the clinical trials. Also included are philosophical considerations surrounding the diagnosis of hypoactive sexual desire disorder and pharmacological treatment of low libido. Based on the review of literature, authors judge flibanserin to be modestly effective and reasonably safe, and discuss the differences in philosophical perspectives with less definitive answers.

Advisory Committee Meeting Document (2015) Flibanserin for the treatment of hypoactive sexual desire disorder in premenopausal women. Bone, Reproductive and Urologic Drugs Advisory Committee Meeting, Drug Safety and Risk Management Advisory Committee. p. i-xvi. http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/drugsafetyandriskmanagementadvisorycommittee/ucm449090.pdf. Accessed 6 Mar 2016

Althof SE, Rosen RC, DeRogatis L, Corty E, Quirk F, Symonds T (2005) Outcome measurement in female sexual dysfunction clinical trials: review and recommendations. J Sex Marital Ther 31:153–166CrossRefPubMed

American Psychiatric Association (2000) Diagnostic and Statistical Manual of Mental Disorders, 4th edition, Textual Revision. American Psychiatric Association, Washington DCCrossRef

American Psychiatric Association (2013) Diagnostic and Statistical Manual of Mental Disorders, 5th edn. American Psychiatric Association, ArlingtonCrossRef

BBC (2015, Aug 19) ‘Female Viagra’—a closer look at flibanserin. http://www.bbc.com/news/health-33984472. Accessed 6 Mar 2016

Bolton D (2008) What is mental disorder?: an essay in philosophy, science, and values. Oxford University Press, OxfordCrossRef

Brotto LA (2010) The DSM diagnostic criteria for hypoactive sexual desire disorder in women. Arch Sex Behav 39:221–239. doi:10.1007/s10508-009-9543-1 CrossRefPubMed

Clayton AH, Dennerstein L, Fisher WA, Kingsberg SA, Perelman MA, Pyke RE (2010) Standards for clinical trials in sexual dysfunction in women: research designs and outcomes assessment. J Sex Med 7:541–560. doi:10.1111/j.1743-6109.2009.01628.x CrossRefPubMed

Clayton AH, DeRogatis LR, Rosen RC, Pyke R (2012) Intended or unintended consequences? The likely implications of raising the bar for sexual dysfunction diagnosis in the proposed DSM‐V revisions: 1. For women with incomplete loss of desire or sexual receptivity. J Sex Med 9:2027–2039. doi:10.1111/j.1743-6109.2012.02850.x CrossRefPubMed

Derogatis LR, Komer L, Katz M, Moreau M, Kimura T, Garcia M Jr, Wunderlich G, Pyke R, VIOLET Trial Investigators (2012) Treatment of hypoactive sexual desire disorder in premenopausal women: efficacy of flibanserin in the VIOLET Study. J Sex Med 9:1074–1085. doi:10.1111/j.1743-6109.2011.02626.x CrossRefPubMed

FDA (2015) ADDYI (flibanserin). FDA product labelling. p 3. http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022526lbl.pdf. Accessed 26 Mar 2016

FDA (2016) CIALIS (tadalafil). FDA product labelling. p 17. http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021368s027lbl.pdf. Accessed 4 Nov 2016

Gellad WF, Flynn KE, Alexander GC (2015) Evaluation of flibanserin: science and advocacy at the FDA. JAMA 314:869–870. doi:10.1001/jama.2015.8405 CrossRefPubMed

Goldschmidt D (2015, August 18) ‘Female Viagra’ gets FDA approval. CNN. http://www.cnn.com/2015/08/18/health/female-viagra-fda-approval/. Accessed 6 Mar 2016

Jaspers L, Feys F, Bramer WM, Franco OH, Leusink P, Laan ET (2016) Efficacy and safety of flibanserin for the treatment of hypoactive sexual desire disorder in women: a systematic review and meta-analysis. JAMA Intern Med 176:453–462. doi:10.1001/jamainternmed.2015.8565 CrossRefPubMed

Joffe HV, Chang C, Sewell C, Easley O, Nguyen C, Dunn S, Lehrfeld K, Lee L, Kim MJ, Slagle AF, Beitz J (2016) FDA approval of flibanserin—treating hypoactive sexual desire disorder. N Engl J Med 374:101–104. doi:10.1056/NEJMp1513686 CrossRefPubMed

Katz M, DeRogatis LR, Ackerman R, Hedges P, Lesko L, Garcia M Jr, Sand M, BEGONIA Trial Investigators (2013) Efficacy of flibanserin in women with hypoactive sexual desire disorder: results from the BEGONIA trial. J Sex Med 10:1807–1815. doi:10.1111/jsm.12189 CrossRefPubMed

Kingsberg SA (2014) Attitudinal survey of women living with low sexual desire. J Womens Health (Larchmt) 23:817–823. doi:10.1089/jwh.2014.4743 CrossRef

Kingsberg SA, Althof SE (2011) Satisfying sexual events as outcome measures in clinical trial of female sexual dysfunction. J Sex Med 8:3262–3270. doi:10.1111/j.1743-6109.2011.02447.x CrossRefPubMed

Meixel A, Yanchar E, Fugh-Berman A (2015) Hypoactive sexual desire disorder: inventing a disease to sell low libido. J Med Ethics 41:859–862. doi:10.1136/medethics-2014-102596 CrossRefPubMed

Nagoski E (2015) Nothing is wrong with your sex drive. The New York Times. http://www.nytimes.com/2015/02/27/opinion/nothing-is-wrong-with-your-sex-drive.html. Accessed 2 Feb 2016

Stahl SM (2015) Mechanism of action of flibanserin, a multifunctional serotonin agonist and antagonist (MSAA), in hypoactive sexual desire disorder. CNS Spectr 20:1–6CrossRefPubMed

Sungur MZ, Gündüz A (2014) A comparison of DSM-IV-TR and DSM-5 definitions for sexual dysfunctions: critiques and challenges. J Sex Med 11:364–373. doi:10.1111/jsm.12379 CrossRefPubMed

Thorp J, Simon J, Dattani D, Taylor L, Kimura T, Garcia M Jr, Lesko L, Pyke R, DAISY Trial Investigators (2012) Treatment of hypoactive sexual desire disorder in premenopausal women: efficacy of flibanserin in the DAISY study. J Sex Med 9:793–804. doi:10.1111/j.1743-6109.2011.02595.x CrossRefPubMed

US Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research (CDER) (2000). Draft guidance for industry: female sexual dysfunction: clinical development of drug products for treatment. http://www.fda.gov/ohrms/dockets/ac/04/briefing/2004-4082B1_02_C-FDA-Appendix-1.pdf. Accessed 6 Mar 2016

Yuko E (2015) The FDA, finances and feminism: why the third time was the charm for so-called ‘female Viagra’. The Huffington Post. 2015, August 24. http://www.huffingtonpost.com/elizabeth-yuko/the-fda-finances-feminism_b_8021828.html. Accessed 6 Mar 2016

Title: Flibanserin and its discontents
Authors: Awais Aftab
Cheryl Chen
Jacob McBride
Publication date: 01-04-2017
Publisher: Springer Vienna
Published in: Archives of Women's Mental Health / Issue 2/2017
Print ISSN: 1434-1816
Electronic ISSN: 1435-1102
DOI: https://doi.org/10.1007/s00737-016-0693-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Flibanserin and its discontents

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2017

A randomized controlled trial: effects of a prenatal depression intervention on perinatal outcomes among Chinese high-risk pregnant women with medically defined complications

Perinatal suicidal ideation and behaviour: psychiatry and adversity

Symptoms of anxiety and depression during pregnancy and their association with low birth weight in Chinese women: a nested case control study

The association between historical childhood sexual abuse and later parenting stress: a systematic review

Prevalence and predictors of positive screening for postpartum depression in minority parturients in the South Bronx

A closer look at the preventative effect of antidepressants in postpartum depression